How Old is Too Old for CAR-T Cell Therapies in Multiple Myeloma?
Authors:
Open Access
- 30 May 2023
- journal article
- editorial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (6) , 343-344
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter AnalysisTransplantation and Cellular Therapy, 2021
- Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphomaBlood, 2020
- Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.Journal of Clinical Oncology, 2020
- B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysisEuropean Journal of Haematology, 2019
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trialLeukemia, 2019
- Geriatric Assessment in Older Adults with Multiple MyelomaJournal of the American Geriatrics Society, 2018
- Toxicities of chimeric antigen receptor T cells: recognition and managementBlood, 2016
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015
- A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly PatientsJournal of the American Geriatrics Society, 2008
- Bone Marrow TransplantationNew England Journal of Medicine, 1994